Dimensional Fund Advisors LP Buys 133,379 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)

Dimensional Fund Advisors LP lifted its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 1,043.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 146,158 shares of the biotechnology company's stock after purchasing an additional 133,379 shares during the quarter. Dimensional Fund Advisors LP owned 0.27% of Astria Therapeutics worth $1,330,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Quest Partners LLC increased its stake in Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 3,112 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Astria Therapeutics by 135.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company's stock valued at $70,000 after purchasing an additional 2,861 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in shares of Astria Therapeutics during the 1st quarter valued at about $200,000. Panagora Asset Management Inc. increased its position in shares of Astria Therapeutics by 104.7% during the 2nd quarter. Panagora Asset Management Inc. now owns 30,926 shares of the biotechnology company's stock valued at $281,000 after purchasing an additional 15,816 shares during the last quarter. Finally, American International Group Inc. increased its position in shares of Astria Therapeutics by 49.4% during the 1st quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company's stock valued at $346,000 after purchasing an additional 8,122 shares during the last quarter. 98.98% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on ATXS shares. TD Cowen assumed coverage on Astria Therapeutics in a research report on Monday, July 29th. They set a "buy" rating and a $35.00 price objective on the stock. Oppenheimer increased their target price on Astria Therapeutics from $25.00 to $26.00 and gave the company an "outperform" rating in a report on Tuesday, August 13th. Wedbush restated an "outperform" rating and set a $22.00 target price on shares of Astria Therapeutics in a report on Tuesday, August 13th. HC Wainwright restated a "buy" rating and set a $16.00 target price on shares of Astria Therapeutics in a report on Friday, September 27th. Finally, Evercore ISI upgraded Astria Therapeutics to a "strong-buy" rating in a report on Wednesday, August 14th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $25.20.

Astria Therapeutics Price Performance

ATXS stock traded up $1.12 on Friday, reaching $11.62. 355,085 shares of the company traded hands, compared to its average volume of 665,530. Astria Therapeutics, Inc. has a one year low of $4.26 and a one year high of $16.90. The company has a market cap of $638.09 million, a P/E ratio of -5.01 and a beta of 0.71. The firm has a fifty day simple moving average of $11.29 and a 200-day simple moving average of $10.54.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last posted its earnings results on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.05). On average, sell-side analysts forecast that Astria Therapeutics, Inc. will post -1.72 EPS for the current year.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.